These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24086104)

  • 21. Patient preferences for depression treatment programs and willingness to pay for treatment.
    Morey E; Thacher JA; Craighead WE
    J Ment Health Policy Econ; 2007 Jun; 10(2):73-85. PubMed ID: 17603148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A discrete choice experiment to understand preferences of patients with type 2 diabetes treated with injectable non-insulinic agents.
    Darbà J; Ascanio M
    Curr Med Res Opin; 2021 Jan; 37(1):37-43. PubMed ID: 33269944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment.
    Hodgkins P; Swinburn P; Solomon D; Yen L; Dewilde S; Lloyd A
    Patient; 2012; 5(1):33-44. PubMed ID: 22077619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway.
    Glenngård AH; Hjelmgren J; Thomsen PH; Tvedten T
    Nord J Psychiatry; 2013 Oct; 67(5):351-9. PubMed ID: 23245636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the value of symptom relief for patients with gastroesophageal reflux disease treatment: willingness to pay using a discrete choice experiment.
    Deal K; Marshall D; Dabrowski D; Charter A; Bukoski M; Moayyedi P
    Value Health; 2013 Jun; 16(4):588-98. PubMed ID: 23796293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment.
    Lloyd A; McIntosh E; Price M
    Pharmacoeconomics; 2005; 23(11):1167-81. PubMed ID: 16277551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes.
    Thieu VT; Robinson S; Kennedy-Martin T; Boye KS; Garcia-Perez LE
    Patient Prefer Adherence; 2019; 13():561-576. PubMed ID: 31114170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A valuation of patients' willingness-to-pay for insulin delivery in diabetes.
    Guimarães C; Marra CA; Colley L; Gill S; Simpson SH; Meneilly GS; Queiroz RH; Lynd LD
    Int J Technol Assess Health Care; 2009 Jul; 25(3):359-66. PubMed ID: 19619355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.
    Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
    Diabetes Ther; 2017 Apr; 8(2):335-353. PubMed ID: 28236271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents.
    Hauber AB; Mohamed AF; Johnson FR; Falvey H
    Diabet Med; 2009 Apr; 26(4):416-24. PubMed ID: 19388973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Men's preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment.
    Mankowski C; Ikenwilo D; Heidenreich S; Ryan M; Nazir J; Newman C; Watson V
    Patient Prefer Adherence; 2016; 10():2407-2417. PubMed ID: 27920507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are caregivers ready for digital? Caregiver preferences for health technology tools to monitor medication adherence among patients with serious mental illness.
    Forma F; Chiu K; Shafrin J; Boskovic DH; Veeranki SP
    Digit Health; 2022; 8():20552076221084472. PubMed ID: 35295765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
    Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
    Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How does patients' quality of life guide their preferences regarding aspects of asthma therapy?: a patient-preference study using discrete-choice experiment methodology.
    Lloyd A; McIntosh E; Williams AE; Kaptein A; Rabe KF
    Patient; 2008 Dec; 1(4):309-16. PubMed ID: 22272998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors Driving Patient Preferences for Growth Hormone Deficiency (GHD) Injection Regimen and Injection Device Features: A Discrete Choice Experiment.
    McNamara M; Turner-Bowker DM; Westhead H; Yaworsky A; Palladino A; Gross H; Pleil A; Loftus J
    Patient Prefer Adherence; 2020; 14():781-793. PubMed ID: 32431492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Socioeconomic differences in preferences and willingness-to-pay for insulin delivery systems in type 1 and type 2 diabetes.
    Guimarães C; Marra CA; Colley L; Gill S; Simpson S; Meneilly G; Queiroz RH; Lynd LD
    Diabetes Technol Ther; 2009 Sep; 11(9):567-73. PubMed ID: 19764835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK.
    Gelhorn HL; Poon JL; Davies EW; Paczkowski R; Curtis SE; Boye KS
    Patient Prefer Adherence; 2015; 9():1611-22. PubMed ID: 26635470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parents' preferences and willingness-to-pay for human papilloma virus vaccines in Thailand.
    Ngorsuraches S; Nawanukool K; Petcharamanee K; Poopantrakool U
    J Pharm Policy Pract; 2015; 8(1):20. PubMed ID: 26199734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What Is Valued Most by Patients With Type 2 Diabetes Mellitus When Selecting Second-Line Antihyperglycemic Medications in China.
    Liu S; Liu J; Yu Y; Si L; Tang C; Liu Z; Chen Y
    Front Pharmacol; 2021; 12():802897. PubMed ID: 35002736
    [No Abstract]   [Full Text] [Related]  

  • 40. Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST).
    Hauber AB; Gonzalez JM; Coombs J; Sirulnik A; Palacios D; Scherzer N
    Patient Prefer Adherence; 2011; 5():307-14. PubMed ID: 21792302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.